Mark Voskoboynik

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee et al. · Annals of Oncology · 2021 · 287 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al. · The Lancet Oncology · 2024 · 155 citations

Medicine, Oncology, Pharmacology +12

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Arun Azad, Mathias Bressel, Hsiang Tan et al. · The Lancet Oncology · 2024 · 111 citations

Medicine, Oncology, Urology +12

First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

Ravit Geva, Mark Voskoboynik, Konstantin Dobrenkov et al. · Cancer · 2020 · 67 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Herui Yao, Min Yan, Zhongsheng Tong et al. · Journal of Clinical Oncology · 2024 · 45 citations

Medicine, Oncology, Pharmacology +17